NEOGENOMICS INC (NEO)
Health Care · Clinical laboratory testing / oncology diagnostics · NASDAQ
Cancer-focused diagnostic laboratory providing specialized oncology and hematologic testing with expert pathologist interpretation across a network of US and UK labs.
What NEOGENOMICS INC does
NeoGenomics is a cancer-focused diagnostic laboratory company that provides oncology testing and consultative services across its network of CAP-accredited and CLIA-certified laboratories in the United States and United Kingdom. The company offers specialized cytogenetic, molecular, and pathology testing services including cytogenetics, FISH, flow cytometry, immunohistochemistry, molecular residual disease (MRD) testing, and morphologic analysis, with professional interpretation by board-certified pathologists and molecular experts.
Themes: ["cancer diagnostics","oncology testing","molecular diagnostics","pathology","hematologic malignancies","precision medicine / genomics"]
Fundamentals
- Price$14.73 as of 2026-07-09 close
- Market cap$1.9B as of 2026-07-10
- 1-year return+95.6% as of 2026-07-09 close
- Net margin-13.3% as of 2026-07-10
- Gross margin+43.1% as of 2026-07-10
- ROE-11.8% as of 2026-07-10
- Debt / equity0.41 as of 2026-07-10
- Revenue growth (YoY)+10.9% as of 2026-07-10
- Beta1.78 as of 2026-07-10
Key risks (from latest filing)
["Regulatory uncertainty around laboratory developed tests (LDTs) and evolving CMS/FDA requirements that could impact reimbursement and business model","Reimbursement pressure from government and commercial payors affecting pricing and volume growth","Supply chain vulnerability to tariffs and trade policy uncertainty impacting laboratory operations and costs"]
Competitors & peers
- Quest Diagnostics (DGX)
- LabCorp (LH)
- Exact Sciences (EXAS)
- Invitae (NVTA)
- Natera (NTRA)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.